quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:30:39·386d
INSIDERFiling
Intra-Cellular Therapies Inc. logo

Chairman and CEO Mates Sharon returned $149,851,020 worth of shares to the company (1,135,235 units at $132.00), closing all direct ownership in the company (SEC Form 4)

ITCI· Intra-Cellular Therapies Inc.
Health Care
Original source

Companies

  • ITCI
    Intra-Cellular Therapies Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateMizuho$132.00
  • Jan 31UpdateCanaccord Genuity$132.00
  • Sep 6UpdatePiper Sandler$92.00
  • Jan 3UpdateRobert W. Baird$83.00
  • Dec 11UpdateTD Cowen$75.00
  • Apr 20UpdateMorgan Stanley$80.00

Related

  • PR357d
    Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
  • SEC374d
    SEC Form 15-12G filed by Intra-Cellular Therapies Inc.
  • SEC378d
    SEC Form EFFECT filed by Intra-Cellular Therapies Inc.
  • INSIDER386d
    Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER386d
    Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER386d
    President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER386d
    Director Van Nostrand Robert L returned $1,496,880 worth of shares to the company (11,340 units at $132.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER386d
    EVP, Chief Commercial Officer Neumann Mark returned $6,971,052 worth of shares to the company (52,811 units at $132.00), closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022